208 related articles for article (PubMed ID: 26876309)
1. Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Teipel SJ; Cavedo E; Grothe MJ; Lista S; Galluzzi S; Colliot O; Chupin M; Bakardjian H; Dormont D; Dubois B; Hampel H;
Neuropharmacology; 2016 Sep; 108():128-35. PubMed ID: 26876309
[TBL] [Abstract][Full Text] [Related]
2. Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.
Cavedo E; Dubois B; Colliot O; Lista S; Croisile B; Tisserand GL; Touchon J; Bonafe A; Ousset PJ; Rouaud O; Ricolfi F; Vighetto A; Pasquier F; Galluzzi S; Delmaire C; Ceccaldi M; Girard N; Lehericy S; Duveau F; Chupin M; Sarazin M; Dormont D; Hampel H;
J Clin Psychiatry; 2016 Dec; 77(12):e1631-e1638. PubMed ID: 27780331
[TBL] [Abstract][Full Text] [Related]
3. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Dubois B; Chupin M; Hampel H; Lista S; Cavedo E; Croisile B; Louis Tisserand G; Touchon J; Bonafe A; Ousset PJ; Ait Ameur A; Rouaud O; Ricolfi F; Vighetto A; Pasquier F; Delmaire C; Ceccaldi M; Girard N; Dufouil C; Lehericy S; Tonelli I; Duveau F; Colliot O; Garnero L; Sarazin M; Dormont D; ;
Alzheimers Dement; 2015 Sep; 11(9):1041-9. PubMed ID: 25596420
[TBL] [Abstract][Full Text] [Related]
4. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
[TBL] [Abstract][Full Text] [Related]
6. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
[TBL] [Abstract][Full Text] [Related]
7. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Wilkinson D; Windfeld K; Colding-Jørgensen E
Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of brain morphometry following donepezil treatment in mild cognitive impairment: volume changes of cortical/subcortical regions and hippocampal subfields.
Kim GW; Kim BC; Park KS; Jeong GW
Sci Rep; 2020 Jul; 10(1):10912. PubMed ID: 32616841
[TBL] [Abstract][Full Text] [Related]
10. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.
Krishnan KR; Charles HC; Doraiswamy PM; Mintzer J; Weisler R; Yu X; Perdomo C; Ieni JR; Rogers S
Am J Psychiatry; 2003 Nov; 160(11):2003-11. PubMed ID: 14594748
[TBL] [Abstract][Full Text] [Related]
11. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
Craft S; Claxton A; Baker LD; Hanson AJ; Cholerton B; Trittschuh EH; Dahl D; Caulder E; Neth B; Montine TJ; Jung Y; Maldjian J; Whitlow C; Friedman S
J Alzheimers Dis; 2017; 57(4):1325-1334. PubMed ID: 28372335
[TBL] [Abstract][Full Text] [Related]
12. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
[TBL] [Abstract][Full Text] [Related]
13. Vitamin E and donepezil for the treatment of mild cognitive impairment.
Petersen RC; Thomas RG; Grundman M; Bennett D; Doody R; Ferris S; Galasko D; Jin S; Kaye J; Levey A; Pfeiffer E; Sano M; van Dyck CH; Thal LJ;
N Engl J Med; 2005 Jun; 352(23):2379-88. PubMed ID: 15829527
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
15. Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study.
Moraes W; Poyares D; Sukys-Claudino L; Guilleminault C; Tufik S
Chest; 2008 Mar; 133(3):677-83. PubMed ID: 18198262
[TBL] [Abstract][Full Text] [Related]
16. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.
Coric V; Salloway S; van Dyck CH; Dubois B; Andreasen N; Brody M; Curtis C; Soininen H; Thein S; Shiovitz T; Pilcher G; Ferris S; Colby S; Kerselaers W; Dockens R; Soares H; Kaplita S; Luo F; Pachai C; Bracoud L; Mintun M; Grill JD; Marek K; Seibyl J; Cedarbaum JM; Albright C; Feldman HH; Berman RM
JAMA Neurol; 2015 Nov; 72(11):1324-33. PubMed ID: 26414022
[TBL] [Abstract][Full Text] [Related]
17. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease.
Doody RS; Dunn JK; Clark CM; Farlow M; Foster NL; Liao T; Gonzales N; Lai E; Massman P
Dement Geriatr Cogn Disord; 2001; 12(4):295-300. PubMed ID: 11351141
[TBL] [Abstract][Full Text] [Related]
18. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
19. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.
Kile S; Au W; Parise C; Rose K; Donnel T; Hankins A; Chan M; Ghassemi A
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):106-112. PubMed ID: 26420886
[TBL] [Abstract][Full Text] [Related]
20. Hippocampus and Basal Forebrain Volumetry for Dementia and Mild Cognitive Impairment Diagnosis: Could It Be Useful in Primary Care?
Teipel SJ; Keller F; Thyrian JR; Strohmaier U; Altiner A; Hoffmann W; Kilimann I
J Alzheimers Dis; 2017; 55(4):1379-1394. PubMed ID: 27834778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
